Biotransformation of silybin and its congeners

Current Drug Metabolism

Volumn 14, Issue 10, 2013, Pages 1009-1021

  Křen, Vladimír ^a   Marhol, Petr ^a   Purchartová, Kateřina ^a   Gabrielová, Eva ^b   Modrianský, Martin ^b  

^a INSTITUTE OF MICROBIOLOGY   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Biotransformation; Cytochrome P450; Diastereoisomers; Glucuronidation; Silibinin; Silybin; Silymarin; Sulfonation

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C8; FLAVONOLIGNAN; ISOSILYBIN A; ISOSILYBIN B; SILIBININ; SILIBININ A; SILIBININ B; SILICRISTIN; SILIDIANIN; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL ACTIVITY; DIASTEREOISOMER; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SULFATION; DRUG TRANSFORMATION; HUMAN; NONHUMAN; STEREOSPECIFICITY;

ANIMALS; ANTIOXIDANTS; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; GLUCURONIDES; HUMANS; SILYMARIN; STEREOISOMERISM;

EID: 84891339569     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200214666131118234507     Document Type: Article

References (110)

1. Simanek, V.; Kren, V.; Ulrichova, J.; Vicar, J.; Cvak, L. Silymarin: What is in the name? An appeal for a change of editorial policy. Hepatology, 2000, 32(2), 442-4.
2. Kroll, D.J.; Shaw, H.S.; Oberlies, N.H. Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr. Cancer Ther., 2007, 6(2), 110-9.
3. Choppin, J.; Desplaces, A. The effects of silybin on experimental phalloidine poisoning. Arzneimittelforschung, 1978, 28(4), 636-41.
4. Wellington, K.; Jarvis, B. Silymarin: A review of its clinical properties in the management of hepatic disorders. BioDrugs, 2001, 15(7), 465-89.
5. Pietrangelo, A.; Borella, F.; Casalgrandi, G.; Montosi, G.; Ceccarelli, D.; Gallesi, D.; Giovannini, F.; Gasparetto, A.; Masini, A. Antioxidant activity of silybin in vivo during long-term iron overload in rats. Gastroenterology, 1995, 109(6), 1941-9.
6. Valenzuela, A.; Guerra, R.; Videla, L.A. Antioxidant properties of the flavonoids silybin and (+)-cyanidanol-3: Comparison with butylated hydroxyanisole and butylated hydroxytoluene. Planta Med., 1986, 6, 438-40.
7. Krecman, V.; Skottova, N.; Walterova, D.; Ulrichova, J.; Simanek, V. Silymarin inhibits the development of diet-induced hypercholesterolemia in rats. Planta Med., 1998, 64(2), 138-42.
8. Skottova, N.; Krecman, V. Silymarin as a potential hypocholesterolaemic drug. Physiol. Res., 1998, 47(1), 1-7.
9. Agarwal, R.; Katiyar, S.K.; Lundgren, D.W.; Mukhtar, H. Inhibitory effect of silymarin, an anti-hepatotoxic flavonoid, on 12-Otetradecanoylphorbol- 13-acetate-induced epidermal ornithine decarboxylase activity and mRNA in SENCAR mice. Carcinogenesis, 1994, 15(6), 1099-103.
10. Deep, G.; Oberlies, N.H.; Kroll, D.J.; Agarwal, R. Identifying the differential effects of silymarin constituents on cell growth and cell cycle regulatory molecules in human prostate cancer cells. Int. J. Cancer, 2008, 123(1), 41-50.
11. Deep, G.; Raina, K.; Singh, R.P.; Oberlies, N.H.; Kroll, D.J.; Agarwal, R. Isosilibinin inhibits advanced human prostate cancer growth in athymic nude mice: Comparison with silymarin and silibinin. Int. J. Cancer, 2008, 123(12), 2750-8.
12. Gazak, R.; Walterova, D.; Kren, V. Silybin and silymarin-new and emerging applications in medicine. Curr. Med. Chem., 2007, 14(3), 315-38.
13. Trouillas, P.; Marsal, P.; Svobodova, A.; Vostalova, J.; Gazak, R.; Hrbac, J.; Sedmera, P.; Kren, V.; Lazzaroni, R.; Duroux, J.L.; Walterova, D. Mechanism of the antioxidant action of silybin and 2,3- dehydrosilybin flavonolignans: A joint experimental and theoretical study. J. Phys. Chem. A, 2008, 112(5), 1054-63.
14. Gazak, R.; Sedmera, P.; Vrbacky, M.; Vostalova, J.; Drahota, Z.; Marhol, P.; Walterova, D.; Kren, V. Molecular mechanisms of silybin and 2,3-dehydrosilybin antiradical activity-role of individual hydroxyl groups. Free Radic. Biol. Med., 2009, 46(6), 745-58.
15. Weyhenmeyer, R.; Mascher, H.; Birkmayer, J. Study on doselinearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay. Int. J. Clin. Pharmacol. Ther. Toxicol., 1992, 30(4), 134-8.
16. Han, Y.H.; Lou, H.X.; Ren, D.M.; Sun, L.R.; Ma, B.; Ji, M. Stereoselective metabolism of silybin diastereoisomers in the glucuronidation process. J. Pharm. Biomed. Anal., 2004, 34(5), 1071-8.
17. Kren, V.; Ulrichova, J.; Kosina, P.; Stevenson, D.; Sedmera, P.; Prikrylova, V.; Halada, P.; Simanek, V. Chemoenzymatic preparation of silybin beta-glucuronides and their biological evaluation. Drug Metab. Dispos., 2000, 28(12), 1513-7.
18. Lee, D.Y.; Liu, Y. Molecular structure and stereochemistry of silybin A, silybin B, isosilybin A, and isosilybin B, Isolated from Silybum marianum (milk thistle). J. Nat. Prod., 2003, 66(9), 1171-4.
19. Kren, V.; Gazak, R.; Purchartova, K.; Marhol, P.; Biedermann, D.; Sedmera, P. Chemoenzymatic preparative separation of silybins A and B. J. Mol. Catal. B: Enzym., 2009, 61(3-4), 247-251.
20. Schrall, R.; Becker, H. Tissue and suspension cultures of Silybum marianum, 2. Formation of flavonolignans by feeding suspension cultures with flavonoids and coniferyl alcohol. Planta Med., 1977, 32(1), 27-32.
21. Davis-Searles, P.R.; Nakanishi, Y.; Kim, N.C.; Graf, T.N.; Oberlies, N.H.; Wani, M.C.; Wall, M.E.; Agarwal, R.; Kroll, D.J. Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Cancer Res., 2005, 65(10), 4448-57.
22. Pliskova, M.; Vondracek, J.; Kren, V.; Gazak, R.; Sedmera, P.; Walterova, D.; Psotova, J.; Simanek, V.; Machala, M. Effects of silymarin flavonolignans and synthetic silybin derivatives on estrogen and aryl hydrocarbon receptor activation. Toxicology, 2005, 215(1-2), 80-9.
23. Gazak, R.; Valentova, K.; Fuksova, K.; Marhol, P.; Kuzma, M.; Medina, M.A.; Oborna, I.; Ulrichova, J.; Kren, V. Synthesis and antiangiogenic activity of new silybin galloyl esters. J. Med. Chem., 2011, 54(20), 7397-407.
24. Kren, V., Sedmera, P., Kubisch, J., Halada, P., Prikrylova, V., Jegorov, A., Cvak, L., Gebhardt, R., Ulrichova, J., and Simanek, V., Glycosylation of silybin. J. Chem. Soc. Perkin 1, 1997, 17, 2467-2474.
25. Kim, N.C.; Graf, T.N.; Sparacino, C.M.; Wani, M.C.; Wall, M.E. Complete isolation and characterization of silybins and isosilybins from milk thistle (Silybum marianum). Org. Biomol. Chem., 2003, 1(10), 1684-9.
26. Monti, D.; Gazak, R.; Marhol, P.; Biedermann, D.; Purchartova, K.; Fedrigo, M.; Riva, S.; Kren, V. Enzymatic kinetic resolution of silybin diastereoisomers. J. Nat. Prod., 2010, 73(4), 613-9.
27. Gazak, R.; Marhol, P.; Purchartova, K.; Monti, D.; Biedermann, D.; Riva, S.; Cvak, L.; Kren, V. Large-scale separation of silybin diastereoisomers using lipases. Proc. Biochem., 2010, 45(10), 1657-1663.
28. Markowitz, J.S.; Zhu, H.J. Limitations of in vitro assessments of the drug interaction potential of botanical supplements. Planta Med., 2012, 78(13), 1421-7.
29. Anzenbacher, P.; Anzenbacherova, E. Cytochromes P450 and metabolism of xenobiotics. Cell. Mol. Life Sci., 2001, 58(5-6), 737-47.
30. Dvorak, Z.; Vrzal, R.; Ulrichova, J. Silybin and dehydrosilybin inhibit cytochrome P450 1A1 catalytic activity: A study in human keratinocytes and human hepatoma cells. Cell Biol. Toxicol., 2006, 22(2), 81-90.
31. Doehmer, J.; Tewes, B.; Klein, K.U.; Gritzko, K.; Muschick, H.; Mengs, U. Assessment of drug-drug interaction for silymarin. Toxicol. In vitro, 2008. 22(3), 610-7.
32. Beckmann-Knopp, S.; Rietbrock, S.; Weyhenmeyer, R.; Bocker, R.H.; Beckurts, K.T.; Lang, W.; Hunz, M.; Fuhr, U. Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol. Toxicol., 2000, 86(6), 250-6.
33. Jancova, P.; Anzenbacherova, E.; Papouskova, B.; Lemr, K.; Luzna, P.; Veinlichova, A.; Anzenbacher, P.; Simanek, V. Silybin is metabolized by cytochrome P450 2C8 in vitro. Drug Metab. Dispos., 2007, 35(11), 2035-9.
34. Gurley, B.J.; Gardner, S.F.; Hubbard, M.A.; Williams, D.K.; Gentry, W.B.; Carrier, J.; Khan, I.A.; Edwards, D.J.; Shah, A. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin. Pharmacol. Ther., 2004, 76(5), 428-40.
35. Upadhyay, G.; Kumar, A.; Singh, M.P. Effect of silymarin on pyrogallol- and rifampicin-induced hepatotoxicity in mouse. Eur. J. Pharmacol., 2007, 565(1-3), 190-201.
36. Kosina, P.; Maurel, P.; Ulrichova, J.; Dvorak, Z. Effect of silybin and its glycosides on the expression of cytochromes P450 1A2 and 3A4 in primary cultures of human hepatocytes. J. Biochem. Mol. Toxicol., 2005. 19(3), 149-53.
37. Doehmer, J.; Weiss, G.; McGregor, G.P.; Appel, K. Assessment of a dry extract from milk thistle (Silybum marianum) for interference with human liver cytochrome-P450 activities. Toxicol. In vitro, 2011, 25(1), 21-7.
38. Sridar, C.; Goosen, T.C.; Kent, U.M.; Williams, J.A.; Hollenberg, P.F. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab. Dispos., 2004, 32(6), 587-94.
39. Brantley, S.J.; Oberlies, N.H.; Kroll, D.J.; Paine, M.F. Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations. J. Pharmacol. Exp. Ther., 2010, 332(3), 1081-7.
40. Rajnarayana, K.; Reddy, M.S.; Vidyasagar, J.; Krishna, D.R. Study on the influence of silymarin pretreatment on metabolism and disposition of metronidazole. Arzneimittelforschung, 2004, 54(2), 109-13.
41. Scambia, G.; De Vincenzo, R.; Ranelletti, F.O.; Panici, P.B.; Ferrandina, G.; D'Agostino, G.; Fattorossi, A.; Bombardelli, E.; Mancuso, S. Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin. Eur. J. Cancer, 1996, 32A(5), 877-82.
42. Ladas, E.J.; Kelly, K.M. Milk thistle: Is there a role for its use as an adjunct therapy in patients with cancer? J. Altern. Complement. Med., 2003, 9(3), 411-6.
43. Invernizzi, R.; Bernuzzi, S.; Ciani, D.; Ascari, E. Silymarine during maintenance therapy of acute promyelocytic leukemia. Haematologica, 1993, 78(5), 340-1.
44. Chlopcikova, S.; Psotova, J.; Miketova, P.; Simanek, V. Chemoprotective effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes. Part I. Silymarin and its flavonolignans. Phytother. Res., 2004. 18(2), 107-10.
45. Zuber, R.; Modriansky, M.; Dvorak, Z.; Rohovsky, P.; Ulrichova, J.; Simanek, V.; Anzenbacher, P. Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities. Phytother. Res., 2002, 16(7), 632-8.
46. Miguez, M.P.; Anundi, I.; Sainz-Pardo, L.A.; Lindros, K.O. Hepatoprotective mechanism of silymarin: no evidence for involvement of cytochrome P450 2E1. Chem. Biol. Interact., 1994, 91(1), 51-63.
47. Brandon-Warner, E.; Sugg, J.A.; Schrum, L.W.; McKillop, I.H. Silibinin inhibits ethanol metabolism and ethanol-dependent cell proliferation in an in vitro model of hepatocellular carcinoma. Cancer Lett., 2010, 291(1), 120-9.
48. Brandon-Warner, E.; Eheim, A.L.; Foureau, D.M.; Walling, T.L.; Schrum, L.W.; McKillop, I.H. Silibinin (Milk Thistle) potentiates ethanol-dependent hepatocellular carcinoma progression in male mice. Cancer Lett., 2012. 326(1), 88-95.
49. Crocenzi, F.A.; Sanchez Pozzi, E.J.; Pellegrino, J.M.; Favre, C.O.; Rodriguez Garay, E.A.; Mottino, A.D.; Coleman, R.; Roma, M.G. Beneficial effects of silymarin on estrogen-induced cholestasis in the rat: A study in vivo and in isolated hepatocyte couplets. Hepatology, 2001, 34(2), 329-39.
50. Venkataramanan, R.; Ramachandran, V.; Komoroski, B.J.; Zhang, S.; Schiff, P.L.; Strom, S.C. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab. Dispos., 2000, 28(11), 1270-3.
51. Brantley, S.J.; Graf, T.N.; Oberlies, N.H.; Paine, M.F. A Systematic Approach to Evaluate Herb-Drug Interaction Mechanisms: Investigation of Milk Thistle Extracts and Eight Isolated Constituents as CYP3A Inhibitors. Drug Metab. Dispos., 2013, 41(9), 1662-70.
52. van Erp, N.P.; Baker, S.D.; Zhao, M.; Rudek, M.A.; Guchelaar, H.J.; Nortier, J.W.; Sparreboom, A.; Gelderblom, H. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin. Cancer Res., 2005, 11(21), 7800-6.
53. Piscitelli, S.C.; Formentini, E.; Burstein, A.H.; Alfaro, R.; Jagannatha, S.; Falloon, J. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy, 2002, 22(5), 551-6.
54. DiCenzo, R.; Shelton, M.; Jordan, K.; Koval, C.; Forrest, A.; Reichman, R.; Morse, G. Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy, 2003, 23(7), 866-70.
55. Li, C.; Lee, M.Y.; Choi, J.S. Effects of silybinin, CYP3A4 and Pglycoprotein inhibitor in vitro, on the bioavailability of loratadine in rats. Pharmazie, 2010, 65(7), 510-4.
56. Lee, C.K.; Choi, J.S. Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats. Pharmacology, 2010, 85(6), 350-6.
57. Kim, C.S.; Choi, S.J.; Park, C.Y.; Li, C.; Choi, J.S. Effects of silybinin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen in rats. Anticancer Res., 2010, 30(1), 79-85.
58. Mooiman, K.D.; Maas-Bakker, R.F.; Moret, E.E.; Beijnen, J.H.; Schellens, J.H.; Meijerman, I. Milk thistle's active components silybin and isosilybin: novel inhibitors of PXR-mediated CYP3A4 induction. Drug Metab. Dispos., 2013, 41(8), 1494-504.
59. Hermann, R.; von Richter, O. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. Planta Med., 2012, 78(13), 1458-77.
60. Gunaratna, C.; Zhang, T. Application of liquid chromatographyelectrospray ionization-ion trap mass spectrometry to investigate the metabolism of silibinin in human liver microsomes. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2003, 794(2), 303-10.
61. Jancova, P.; Anzenbacher, P.; Anzenbacherova, E. Phase II drug metabolizing enzymes. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub., 2010, 154(2), 103-16.
62. Wu, J.W.; Lin, L.C.; Hung, S.C.; Chi, C.W.; Tsai, T.H. Analysis of silibinin in rat plasma and bile for hepatobiliary excretion and oral bioavailability application. J. Pharm. Biomed. Anal., 2007, 45(4), 635-41.
63. Miranda, S.R., Lee, J.K., Brouwer, K.L., Wen, Z., Smith, P.C., and Hawke, R.L., Hepatic metabolism and biliary excretion of silymarin flavonolignans in isolated perfused rat livers: role of multidrug resistance-associated protein 2 (Abcc2). Drug Metab. Dispos., 2008, 36(11): p. 2219-26.
64. Wang, L.Q.; James, M.O. Inhibition of sulfotransferases by xenobiotics. Curr. Drug Metab., 2006, 7(1), 83-104.
65. Kauffman, F.C. Sulfonation in pharmacology and toxicology. Drug Metabol. Rev., 2004, 36(3-4), 823-843.
66. Strott, C.A. Sulfonation and molecular action. Endocr. Rev., 2002, 23(5), 703-32.
67. Glatt, H.; Boeing, H.; Engelke, C.E.; Ma, L.; Kuhlow, A.; Pabel, U.; Pomplun, D.; Teubner, W.; Meinl, W. Human cytosolic sulphotransferases: genetics, characteristics, toxicological aspects. Mutat. Res., 2001, 482(1-2), 27-40.
68. Coughtrie, M.W.; Sharp, S.; Maxwell, K.; Innes, N.P. Biology and function of the reversible sulfation pathway catalysed by human sulfotransferases and sulfatases. Chem. Biol. Interact., 1998, 109(1-3), 3-27.
69. Kauffman, F.C.; Whittaker, M.; Anundi, I.; Thurman, R.G. Futile cycling of a sulfate conjugate by isolated hepatocytes. Mol. Pharmacol., 1991, 39(3), 414-20.
70. Tan, E.; Pang, K.S. Sulfation is rate limiting in the futile cycling between estrone and estrone sulfate in enriched periportal and perivenous rat hepatocytes. Drug Metab. Dispos., 2001, 29(3), 335-46.
71. Hoh, C.; Boocock, D.; Marczylo, T.; Singh, R.; Berry, D.P.; Dennison, A.R.; Hemingway, D.; Miller, A.; West, K.; Euden, S.; Garcea, G.; Farmer, P.B.; Steward, W.P.; Gescher, A.J. Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clin. Cancer Res., 2006, 12(9), 2944-50.
72. Purchartova, K.; Engels, L.; Marhol, P.; Sulc, M.; Kuzma, M.; Slamova, K.; Elling, L.; Kren, V. Enzymatic preparation of silybin phase II metabolites: sulfation using aryl sulfotransferase from rat liver. Appl. Microbiol. Biotechnol., 2013, 97(24), 10391-8.
73. Marhol, P.; Hartog, A.F.; van der Horst, M.A.; Wever, R.; Purchartová, K.; Fuksová, K.; Kuzma, M.; Cvǎka, J.; Kren, V. Preparation of silybin and isosilybin sulfates by sulfotransferase from Desulfitobacterium hafniense. J. Mol. Catal. B: Enzymatic, 2013, 89, 24-27.
74. Zarrelli, A.; Sgambato, A.; Petito, V.; De Napoli, L.; Previtera, L.; Di Fabio, G. New C-23 modified of silybin and 2,3-dehydrosilybin: synthesis and preliminary evaluation of antioxidant properties. Bioorg. Med. Chem. Lett., 2011, 21(15), 4389-92.
75. Abourashed, E.A.; Mikell, J.R.; Khan, I.A. Bioconversion of silybin to Phase I and II microbial metabolites with retained antioxidant activity. Bioorg. Med. Chem., 2012, 20(9), 2784-8.
76. Agarwal, C.; Wadhwa, R.; Deep, G.; Biedermann, D.; Gazak, R.; Kren, V.; Agarwal, R. Anti-cancer efficacy of silybin derivatives - a structure-activity relationship. PLoS One, 2013, 8(3), e60074.
77. Manach, C.; Scalbert, A.; Morand, C.; Remesy, C.; Jimenez, L. Polyphenols: food sources and bioavailability. Am. J. Clin. Nutr., 2004, 79(5), 727-47.
78. Chen, Y.; Xie, S.; Chen, S.; Zeng, S. Glucuronidation of flavonoids by recombinant UGT1A3 and UGT1A9. Biochem. Pharmacol., 2008, 76(3), 416-25.
79. Fisher, M.B.; Paine, M.F.; Strelevitz, T.J.; Wrighton, S.A. The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab. Rev., 2001, 33(3-4), 273-97.
80. King, C.D.; Rios, G.R.; Assouline, J.A.; Tephly, T.R. Expression of UDP-glucuronosyltransferases (UGTs) 2B7 and 1A6 in the human brain and identification of 5-hydroxytryptamine as a substrate. Arch. Biochem. Biophys., 1999, 365(1), 156-62.
81. King, C.D.; Rios, G.R.; Green, M.D.; Tephly, T.R. UDPglucuronosyltransferases. Curr. Drug Metab., 2000, 1(2), 143-61.
82. Jancova, P.; Siller, M.; Anzenbacherova, E.; Kren, V.; Anzenbacher, P.; Simanek, V. Evidence for differences in regioselective and stereoselective glucuronidation of silybin diastereomers from milk thistle (Silybum marianum) by human UDP-glucuronosyltransferases. Xenobiotica, 2011, 41(9), 743-51.
83. Cheng, Z.; Radominska-Pandya, A.; Tephly, T.R. Studies on the substrate specificity of human intestinal UDP- lucuronosyltransferases 1A8 and 1A10. Drug Metab. Dispos., 1999, 27(10), 1165-70.
84. Tukey, R.H.; Strassburg, C.P. Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Mol. Pharmacol., 2001, 59(3), 405-14.
85. Gregory, P.A.; Lewinsky, R.H.; Gardner-Stephen, D.A.; Mackenzie, P.I. Regulation of UDP glucuronosyltransferases in the gastrointestinal tract. Toxicol. Appl. Pharmacol., 2004, 199(3), 354-63.
86. Letteron, P.; Labbe, G.; Degott, C.; Berson, A.; Fromenty, B.; Delaforge, M.; Larrey, D.; Pessayre, D. Mechanism for the protective effects of silymarin against carbon tetrachloride-induced lipid peroxidation and hepatotoxicity in mice. Evidence that silymarin acts both as an inhibitor of metabolic activation and as a chainbreaking antioxidant. Biochem. Pharmacol., 1990, 39(12), 2027-34.
87. Bartholomaeus, A.R.; Bolton, R.; Ahokas, J.T. Inhibition of rat liver cytosolic glutathione S-transferase by silybin. Xenobiotica, 1994, 24(1), 17-24.
88. Zhao, J.; Agarwal, R. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: Implications in cancer chemoprevention. Carcinogenesis, 1999, 20(11), 2101-8.
89. D'Andrea, V.; Perez, L.M.; Sanchez Pozzi, E.J. Inhibition of rat liver UDP-glucuronosyltransferase by silymarin and the metabolite silibinin- glucuronide. Life Sci., 2005, 77(6), 683-92.
90. Flaig, T.W.; Gustafson, D.L.; Su, L.J.; Zirrolli, J.A.; Crighton, F.; Harrison, G.S.; Pierson, A.S.; Agarwal, R.; Glode, L.M. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest. New Drugs, 2007, 25(2), 139-46.
91. Kim, D.H.; Jin, Y.H.; Park, J.B.; Kobashi, K., Silymarin and its components are inhibitors of beta-glucuronidase. Biol. Pharm. Bull., 1994, 17(3), 443-5.
92. Portenoy, R.K.; Thaler, H.T.; Inturrisi, C.E.; Friedlander-Klar, H.; Foley, K.M. The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function. Clin. Pharmacol. Ther., 1992, 51(4), 422-31.
93. Kren, V.; Martinkova, L. Glycosides in medicine: "The role of glycosidic residue in biological activity". Curr. Med. Chem., 2001, 8(11), 1303-28.
94. Barua, A.B.; Sidell, N. Retinoyl beta-glucuronide: A biologically active interesting retinoid. J. Nutr., 2004, 134(1), 286S-289S
95. Ashcroft, F.M.; Gribble, F.M. New windows on the mechanism of action of K(ATP) channel openers. Trends Pharmacol. Sci., 2000, 21(11), 439-45.
96. Zhu, H.J.; Brinda, B.J.; Chavin, K.D.; Bernstein, H.J.; Patrick, K.S.; Markowitz, J.S. An assessment of pharmacokinetics and antioxidant activity of free silymarin flavonolignans in healthy volunteers: A dose escalation study. Drug Metab. Dispos., 2013, 41(9), 1679-85.
97. Schandalik, R.; Gatti, G.; Perucca, E. Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. Arzneimittelforschung, 1992, 42(7), 964-8.
98. Schandalik, R.; Perucca, E. Pharmacokinetics of silybin following oral administration of silipide in patients with extrahepatic biliary obstruction. Drugs Exp. Clin. Res., 1994, 20(1), 37-42.
99. Wu, J.W.; Lin, L.C.; Hung, S.C.; Lin, C.H.; Chi, C.W.; Tsai, T.H. Hepatobiliary excretion of silibinin in normal and liver cirrhotic rats. Drug Metab. Dispos., 2008, 36(3), 589-96.
100. Kock, K.; Xie, Y.; Hawke, R.L.; Oberlies, N.H.; Brouwer, K.L. Interaction of silymarin flavonolignans with organic aniontransporting polypeptides. Drug Metab. Dispos., 2013, 41(5), 958-65.
101. Wen, Z.; Dumas, T.E.; Schrieber, S.J.; Hawke, R.L.; Fried, M.W.; Smith, P.C. Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab. Dispos., 2008, 36(1), 65-72.
102. Javed, S.; Kohli, K.; Ali, M. Reassessing bioavailability of silymarin. Altern. Med. Rev., 2011, 16(3), 239-49.
103. Woo, J.S.; Kim, T.S.; Park, J.H.; Chi, S.C. Formulation and biopharmaceutical evaluation of silymarin using SMEDDS. Arch. Pharm. Res., 2007, 30(1), 82-9.
104. Theodosiou, E.; Purchartova, K.; Stamatis, H.; Kolisis, F.; Kren, V. Bioavailability of silymarin flavonolignans: drug formulations and biotransformation. Phytochem. Rev., 2013.
105. Panapisal, V.; Charoensri, S.; Tantituvanont, A. Formulation of microemulsion systems for dermal delivery of silymarin. AAPS PharmSciTech., 2012, 13(2), 389-99.
106. El-Samaligy, M.S.; Afifi, N.N.; Mahmoud, E.A. Evaluation of hybrid liposomes-encapsulated silymarin regarding physical stability and in vivo performance. Int. J. Pharm., 2006, 319(1-2), 121-9.
107. Voinovich, D.; Perissutti, B.; Grassi, M.; Passerini, N.; Bigotto, A. Solid state mechanochemical activation of Silybum marianum dry extract with betacyclodextrins: Characterization and bioavailability of the coground systems. J. Pharm. Sci., 2009, 98(11), 4119-29.
108. Kubisch, J.; Sedmera, P.; Halada, P.; Gazak, R.; Skottova, N. Simanek, V.; Kren, V. Chemoenzymatic preparation of oligoglycosides of silybin, the flavonolignan from Silybum marianum. Heterocycles, 2001, 54(2), 901-915.
109. Pifferi, G.; Pace, R.; Conti, M. Synthesis and antihepatotoxic activity of silybin 11-O-phosphate. Farmaco, 1994, 49(1), 75-6.
110. Gazak, R.; Sedmera, P.; Marzorati, M.; Riva, S.; Kren, V. Laccasemediated dimerization of the flavonolignans silybin. J. Mol. Catal. B: Enzymatic, 2008, 50(2-4), 87-92